MELBOURNE, May 10, 2023 – (ACN Newswire) – Agfa HealthCare is pleased to announce that it has signed a five-plus-five-year agreement with Northern Health, in Melbourne, Australia. Agfa's latest generation of the Enterprise Imaging 8.2 Platform for Radiology, including RUBEE(R) for AI framework, will enhance the provider's healthcare delivery capabilities. Enterprise Imaging innovations will bring "life in flow" to radiologists, and deliver advanced solutions, automation and efficient workflows which enables clinicians to stay focused on patient diagnosis and treatment.

Northern Health is a prominent public healthcare provider in Melbourne's Northern Region, which is one of the fastest-growing communities in Australia. Established in 1998, Northern Health has become a vital part of the region's healthcare ecosystem by delivering high-quality healthcare services to its diverse and rapidly growing population. The organization's commitment to providing exceptional healthcare has led to the expansion of its services, which now include a broad range of specialist acute medical, surgical, maternity, sub-acute, and ambulatory health services across multiple locations, including Northern Hospital Epping, Broadmeadows Hospital, Craigieburn Centre, and the Bundoora Centre.

Northern Health joins the growing number of Australian healthcare providers, including Austin Health, Eastern Health, Adventist Healthcare and Sunshine Coast Hospital, who are already leveraging the benefits of the Agfa HealthCare Enterprise Imaging solution.

Enterprise Imaging innovations providing "life in flow" to Radiologists

"The choice of Agfa's Enterprise Imaging platform aligns with our vision to deliver high-quality care and transform healthcare services through carefully considered investments in innovative technologies. Our strategic cooperation with Agfa HealthCare is a significant step forward in our quest to advance excellence in healthcare delivery in Melbourne's North. Agfa HealthCare will provide advanced imaging IT functionalities, including AI clinical decision support to our Imaging program. We are delighted to take this first step in what we trust will be a long and beneficial relationship between Northern Health and Agfa HealthCare," says Dr. Terry Kok, Director of Imaging for Northern Health.

"We are proud to partner with Northern Health in implementing our latest generation of the Enterprise Imaging platform that helps manage resource allocation, improve productivity, and provide clinical confidence with embedded AI capabilities. Today, radiologists face multiple pressure points and a constant demand to improve efficiencies of care delivery, while managing ever-greater volumes of incoming information. Our comprehensive medical imaging platform empowers radiologists to focus on patient care and confident diagnosis while increasing productivity and supporting their own well-being. In Agfa HealthCare we call it 'Life in flow,'" says Jamie Osmond, Managing Director ASPAC for Agfa HealthCare.

"RUBEE(R) for AI keeps radiologists in their flow while laying the foundation and framework for analytically intelligent 'clinical packages' seamlessly embedded within Agfa HealthCare Enterprise Imaging. By creating an efficient and effective work experience for radiologists, the Chest X-ray AI Analysis package powered by RUBEE(R) and Lunit INSIGHT CXR will provide radiologists diagnostic confidence, optimize reading performance, and help improve productivity and overall delivery of patient care," says Dr. Anjum Ahmed, Global Chief Medical Officer and Director Innovations for Agfa HealthCare.

Agfa's Enterprise Imaging for Radiology is a comprehensive medical imaging platform that enables healthcare providers to capture, manage, store and distribute images and related data across the enterprise. Designed to support radiologists' work at the top of their craft, its powerful automation features eliminate many of the menial tasks that stand in the way of doing more impactful work. The system is built to foster collaboration across departments, specialties, regions and time zones, so everyone can provide the best care to patients.

Contact Information
Miriam Ladin
Marketing and Communication Americas
miriam.ladin@agfa.com
+1 978 284 7777

Agnieszka Kravic-Dubois
Marketing Communications
agnieszka.kravic-dubois@agfa.com
+32494561389

SOURCE: Agfa HealthCare

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

HONG KONG, May 8, 2023 – (ACN Newswire) – OrbusNeich Medical Group Holdings Limited ("OrbusNeich" or the "Group"; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, announced today that the high-pressure three-wire scoring balloon dilatation catheter Scoreflex TRIO developed and manufactured by its wholly-owned subsidiary OrbusNeich Medical (Shenzhen) Company Limited, has been used successfully in a PCI procedure for a 65-year-old patient with severe coronary artery stenosis and calcification. This first case of success marks the beginning of the clinical study across China for obtaining the product approval.

The principal investigator of the clinical study is the team led by Prof. Ge Junbo, Academician Zhongshan Hospital, Fudan University. Following the successful procedure on the first patient, the team highly commended the product, recognizing its ability to provide patients with a safe and effective treatment option.

Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, "OrbusNeich has launched earlier Scoreflex and Scoreflex NC scoring balloons in Mainland China, which are respectively the first scoring balloon and first high-pressure scoring balloon approved by the National Medical Products Administration. The clinical study on Scoreflex TRIO has officially begun now in Mainland China with the first successful trial recorded. The Group will continue to strive to provide more treatment options to patients in Mainland China. Scoreflex TRIO works in a way that can minimize damage to the interior of the arteries, making relevant procedures safer and more likely to succeed. Launched in Japan in 2021, it saw the Group achieving considerable growth in sales in Japan in 2022, while providing an effective and safe medical solution to many patients. The clinical study team led by famed Academician Ge Junbo has profound professional knowledge and clinical experience, hence we are confident of speeding up the study. In the past two decades, OrbusNeich has the service of very strong R&D and manufacturing teams and has also worked closely with clinical personnel to develop and launch interventional devices for PCI and PTA procedures to meet market demand. In the future, building on this solid foundation, the Group will strive to provide a variety of endovascular and structural heart interventional products to effectively improve the patients' quality of life."

About Scoreflex TRIO
Scoreflex TRIO is the first China-made proprietary coronary three-wire scoring balloon dilatation catheter, developed by OrbusNeich Medical (Shenzhen) Company Limited. The product, through the radial or femoral arteries, channels the guidewires to the target lesions of the coronary arteries. The guidewire and the two integral wires on the balloon act as the external scoring elements, which can generate focal forces on the luminal surface of the balloon, allowing the balloon to open up the coronary lesions and dilate the narrowed coronary arteries at lower pressure, thus effectively stretch the diseased parts and prevent obvious intimal tear and dissection, thereby help improve blood flow and myocardial perfusion. Serving as the pre-dilatation balloon catheter in PCI, Scoreflex TRIO's longitudinal focused force angioplasty [FFA] mechanism can further reduce residual stenosis and improve procedural success relative to ordinary balloon dilation. It can also lower the chances of vascular intimal tear, reduce vascular damage and inflammation, enhancing procedural safety and reducing recurrence of stenosis. FFA mechanism of action of the high-pressure three-wire scoring balloon dilatation catheter allows vessel dilation at lower balloon pressure, such longitudinal progressive angioplasty can minimize vascular intimal damage, increase minimum lumen diameter and reduce residual stenosis.

About OrbusNeich Medical Group Holdings Limited
OrbusNeich is a major global medical device manufacturer specialized in interventional instruments for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, OrbusNeich sells products to over 70 countries and regions worldwide, and it is also the only PCI balloon manufacturer headquartered in China that ranked among the top 6 players in all major overseas PCI balloon markets including Japan (Ranked No. 2), Europe (Ranked No. 4), and the U.S. (Ranked No. 6) in terms of sales volume of PCI balloons in 2021 in accordance with the CIC Report. In addition, in terms of sales volume of PTA balloons in 2021, it ranked No. 3 in Japan and No. 4 in the U.S., respectively. It also specializes in coronary stent products and is actively expanding into neuro vascular intervention and structural heart disease areas. OrbusNeich owns more than 180 granted patents globally. Its in-house R&D team has over twenty years of product development experience and has developed proprietary, world leading technologies.

For more details, please visit the Group's official website: https://orbusneich.com/


Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

LOD, ISRAEL, May 4, 2023 – (ACN Newswire) – NovaSight, a pediatric-focused eyecare MedTech company, announced today that its CureSight binocular digital treatment system for amblyopia (lazy eye) has been named "Best New Technology Solution for Ophthalmology" in the 7th annual MedTech Breakthrough Awards program. The award program is conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies, and products in the global health and medical technology market.

NovaSight provides pediatric patients with eye-tracking based digital vision care solutions by focusing on three major verticals: treatment, diagnostics, and prevention of visual health impairments.

CureSight is an FDA-cleared and CE marked eye-tracking based amblyopia treatment system, designed to replace the traditional eye patching. The treatment is carried out while the patient watches his favorite streamed content from the comfort of his home. By tracking the gaze position of the dominant eye in real-time, the CureSight system blurs its center of vision, while keeping the rest of the image sharp – and providing the amblyopic eye with a normal, high contrast image. This stimulates the brain to complete the blurred image from the amblyopic eye, improving its acuity and developing stereoacuity as the eyes learn to work together.

"Amblyopia, or what's known as 'lazy-eye' affects three percent of the population and puts the patients at risk for eventual vision loss. The gold standard treatment for lazy eye has so far consisted of placing a patch over the strong eye – an old-fashioned solution which suffers from very low compliance," said James Johnson, managing director, MedTech Breakthrough. "With the breakthrough of CureSight's binocular treatment from NovaSight, children develop stereoscopic vision, which is difficult to achieve with the monocular nature of the traditional patching treatment. This breakthrough technology helps to shift treatment into the digital age and we are thrilled to congratulate the NovaSight team for taking home a well-deserved 2023 MedTech Breakthrough Award."

The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories, including Telehealth, Clinical Administration, Patient Engagement, Electronic Health Records (EHR), Virtual Care, Medical Devices, Medical Data and many more. This year's program attracted more than 4,000 nominations from over 17 different countries throughout the world.

"We are proud to be named 'Best New Technology Solution for Ophthalmology' acknowledging our mission to prevent vision impairments among pediatric patients by developing solutions that are specifically designed for the unique needs and attention span of children" said Ran Yam, NovaSight co-founder and CEO. "In a recent pivotal trial which was the basis for our FDA approval, we compared the improvement in visual outcomes (visual acuity and stereoacuity) achieved by CureSight versus the traditional eye patch. This is the first ever pivotal trial where a digital device was shown to be non-inferior to eye patching for amblyopia treatment in children. We will continue to strive to change the lives of millions of children by introducing eye tracking based vision care solutions."

Additionally, the CureSight system is connected to a dedicated cloud platform which allows the physician to monitor treatment progress and compliance remotely. The eye care provider receives a comprehensive patient vision summary, and progress reports and real-time monitoring of the child's treatment are easily accessible.

CureSight was officially launched in the US and Italy earlier this year with exceptional early adoption by the pediatric ophthalmology community and their patients. Equipped with 3 unique CPT codes in the US assigned by the American Medical Association (AMA) last year, NovaSight is pursuing broad coverage with the aim of making CureSight easily accessible to patients whose future vision and eye health depend on the treatment that they receive in their early years.

About NovaSight

NovaSight is an Israeli MedTech company that focuses on bringing pediatric vision care into the digital age. Founded in 2016, NovaSight has experienced rapid growth by delivering complete end-to-end eye-tracking-based solutions for accurate assessment and treatment of early vision disorders.

NovaSight offers two flagship products, both ideally positioned for remote diagnostics and home treatment: The CureSight(TM) system is an eye tracking-based treatment for lazy eye designed to replace traditional eye patching. The EyeSwift(R) PRO system is a comprehensive vision assessment device that accurately and objectively screens for multiple vision impairments within seconds. Additional pipeline products include the TrackSight(TM) digital solution for myopia (short-sightedness) control, targeted to provide an affordable and accessible solution to help in combating the myopia global epidemic, which is growing at an alarming rate.

NovaSight's management and advisory board is composed of accomplished executives, physicians, researchers, and key opinion leaders in the field of vision care.

About MedTech Breakthrough

Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence and innovation in medical & health technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough healthcare and medical companies and products in categories that include Patient Experience & Engagement, Health & Fitness, Medical Devices, Clinical Administration, Connected Healthcare, Medical Data, Healthcare Cybersecurity and more. For more information visit MedTechBreakthrough.com.

Contact Information
Jenny Goldman
Marketing manager
jenny@nova-sight.com
+972 50 9123235

SOURCE: NovaSight Ltd.

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com